Innovate Biopharmaceuticals
Innovate Biopharmaceuticals is a publicly traded clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases, including celiac disease, NASH, Crohn’s, and ulcerative colitis. The company owns all global rights to its products, backed by over 150 patents worldwide, and is led by an experienced management team dedicated to bringing innovative therapeutics to market.
Industries
Nr. of Employees
small (1-50)
Innovate Biopharmaceuticals
8601 Six Forks Road, Suite 400, Raleigh, NC 27615
Products
INN-202 (celiac disease candidate)
Clinical-stage therapeutic candidate entering Phase 3 for treatment of celiac disease; reported Fast Track regulatory designation.
INN-217 (NASH candidate)
Candidate entering Phase 1/2 for nonalcoholic steatohepatitis (NASH), to be evaluated alone or in combination with other agents.
INN-289 (Crohn's disease candidate)
Candidate entering Phase 1 for a subset of Crohn's disease; development focused on inflammatory bowel disease mechanisms.
INN-108 (ulcerative colitis candidate)
Oral small-molecule candidate developed for mild to moderate ulcerative colitis; completed Phase 1 and entering Phase 2 clinical testing.
INN-329 (secretin for MRCP imaging enhancement)
Peptide-based diagnostic adjunct intended to enhance pancreatic-duct visualization during MRCP by stimulating pancreatic secretions; clinical data includes a Phase III study.
INN-202 (celiac disease candidate)
Clinical-stage therapeutic candidate entering Phase 3 for treatment of celiac disease; reported Fast Track regulatory designation.
INN-217 (NASH candidate)
Candidate entering Phase 1/2 for nonalcoholic steatohepatitis (NASH), to be evaluated alone or in combination with other agents.
INN-289 (Crohn's disease candidate)
Candidate entering Phase 1 for a subset of Crohn's disease; development focused on inflammatory bowel disease mechanisms.
INN-108 (ulcerative colitis candidate)
Oral small-molecule candidate developed for mild to moderate ulcerative colitis; completed Phase 1 and entering Phase 2 clinical testing.
INN-329 (secretin for MRCP imaging enhancement)
Peptide-based diagnostic adjunct intended to enhance pancreatic-duct visualization during MRCP by stimulating pancreatic secretions; clinical data includes a Phase III study.
Services
Seeking development and commercialization partners globally and reviewing GI candidates for in-licensing.
Mobile and web-based pharmacy services enabling account management, refill requests, online ordering, medication reminders and live customer support.
Seeking development and commercialization partners globally and reviewing GI candidates for in-licensing.
Mobile and web-based pharmacy services enabling account management, refill requests, online ordering, medication reminders and live customer support.
Expertise Areas
- Clinical trial management
- Gastroenterology therapeutics
- Formulation development and CMC
- Peptide therapeutics and diagnostic adjuncts
Key Technologies
- Small-molecule oral therapeutics
- Peptide hormone therapeutics
- Oral formulation enabling technologies
- MRCP imaging enhancement